Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iqymune in CIDP
NCT02293460Phase 3Completed
- Sponsor
- LFB Group
- Start
- May 2015
- Primary completion
- Sep 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of IqYmune in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by LFB Group. Started May 2015; status: completed.
02
Drugs
IqYmune
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT02293460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293460.